Candel Therapeutics, Inc. (NASDAQ:CADL) Director Paul B. Manning Acquires 1,250,000 Shares

Candel Therapeutics, Inc. (NASDAQ:CADL) Director Paul B. Manning bought 1,250,000 shares of Candel Therapeutics stock in a transaction on Monday, December 16th. The stock was acquired at an average cost of $6.00 per share, with a total value of $7,500,000.00. Following the acquisition, the director now owns 1,303,752 shares of the company’s stock, valued at $7,822,512. This trade represents a 2,325.49 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Candel Therapeutics Stock Performance

Shares of CADL opened at $6.53 on Thursday. Candel Therapeutics, Inc. has a 12-month low of $1.02 and a 12-month high of $14.60. The stock has a market cap of $212.07 million, a P/E ratio of -3.77 and a beta of -0.95. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 1.66. The company has a 50-day moving average of $5.33 and a two-hundred day moving average of $6.02.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective (up previously from $11.00) on shares of Candel Therapeutics in a research note on Wednesday.

Institutional Investors Weigh In On Candel Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 DIFC Ltd acquired a new position in Candel Therapeutics in the 2nd quarter valued at about $31,000. FMR LLC purchased a new position in shares of Candel Therapeutics during the third quarter valued at approximately $46,000. MetLife Investment Management LLC purchased a new stake in Candel Therapeutics in the 3rd quarter worth approximately $87,000. Atom Investors LP acquired a new position in Candel Therapeutics in the 3rd quarter valued at $103,000. Finally, Rhumbline Advisers acquired a new stake in shares of Candel Therapeutics during the second quarter worth $143,000. Hedge funds and other institutional investors own 13.93% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.